The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.
Please note that trial statuses change frequently. For the most up-to-date information, please contact the Research Department at 510.204.4155.
Breast Tumor and Blood markers for Molecular Diagnosis of Breast Diseases and Monitoring of Breast Cancer Treatment and Follow-up
Primary and Secondary Prevention of Osteoporosis-Related Fracture: The Use of DEXA and FRAX Results in a Community–based Practice
Investigator: Su-Ying Liang, Ph.D.